Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.33 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543714 | 0.96 | AKR1C1 (0.56) | AKR1C1HDAC4KMT2AMEN1NPSR1 | |
| SCHEMBL3539518 | 0.95 | AKR1C1 (0.55) | AKR1C1HDAC4KMT2AMEN1NPSR1 | |
| SCHEMBL27987361 | 0.93 | AKR1C1 (0.46) | AKR1C1HDAC4KMT2ANPSR1HSD11B1 | |
| SCHEMBL27987684 | 0.84 | AKR1C1 (0.38) | AKR1C1HDAC4THRBTDP1KMT2A | |
| SCHEMBL3545426 | 0.80 | CHRM3 (0.37) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15067903 | 0.77 | LMNA (0.37) | AKR1C1TDP1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3538579 | 0.77 | CHRM3 (0.40) | AKR1C1HDAC4KMT2AMEN1HSD11B1 | |
| SCHEMBL746495 | 0.73 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1667343 | 0.72 | AKR1C1 (0.91) | AKR1C1HDAC4KMT2AMEN1NPSR1 | |
| SCHEMBL3538190 | 0.72 | LMNA (0.33) | AKR1C1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| CN-104245688-A | Indole and indazole compounds that activate ampk | PFIZER | 2014-12-24 | — | — | CN | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | AKR1C1 824/4885HDAC4 1043/4885THRB 1128/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | AKR1C1 862/4885HDAC4 895/4885THRB 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.